XML 35 R27.htm IDEA: XBRL DOCUMENT v3.26.1
Summary of Significant Accounting Policies - Summary of Segment Profit or Loss Including Significant Segment Expenses (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting Information, Profit (Loss) [Abstract]            
Collaboration revenue $ 3,320   $ 7,874   $ 4,366 $ 11,548
Less:            
Compensation and benefits 7,067   14,262   15,315 30,819
Lab expenses and outside research services 4,809   2,903   8,256 6,127
Clinical supply costs 3,028   3,873   4,407 6,947
Clinical trials 1,371   7,081   4,755 14,094
Support functions 6,123   7,701   12,423 15,987
Other segment expenses [1] 5,315   6,192   8,522 16,407
Total operating expenses 27,713   42,012   53,678 90,381
Loss from operations (24,393)   (34,138)   (49,312) (78,833)
Other income, net 1,533   3,614   3,522 7,838
Income tax 130   0   130 0
Net loss $ (22,990) $ (22,930) $ (30,524) $ (40,471) $ (45,920) $ (70,995)
[1] Other segment expenses include consultants & contractor expense, contra-R&D expense for GSK collaboration, depreciation expense, impairment loss, restructuring expense, and stock-based compensation expense.